Samsung Medical Center Performs World’s First Procedure Using Cutting-Edge Brain Aneurysm Stent
Pioneering Use of Stryker's 'Surpass Elite Flow Diverter' in July
In a landmark achievement for neurovascular medicine, Samsung Medical Center (SMC) in Seoul has performed the world’s first procedure using Stryker's latest brain aneurysm stent equipment, the Surpass Elite Flow Diverter. The procedure was completed successfully in July, and the patient was discharged just three days later.
The Surpass Elite Flow Diverter, a recent innovation from the American medical technology company Stryker, received approval from South Korea’s Ministry of Food and Drug Safety (MFDS) in July of last year. The equipment is scheduled for its first use in the United States in September.
In preparation for the U.S. debut, two American neurosurgeons—Professor Alexander Lewis Coon of St. Joseph’s Hospital and Professor Justin A. Singer of Spectrum Health Medical Group—visited SMC to exchange insights and expertise.
The Surpass Elite Flow Diverter features a sophisticated design that regulates cerebral blood flow, preventing direct circulation into the aneurysm. This approach reduces the risk of aneurysm enlargement or rupture and minimizes the likelihood of unexpected blood clot formation by limiting the body’s recognition of the stent as a foreign object. It is particularly suited for large or complex, non-ruptured aneurysms that are challenging to treat with conventional endovascular techniques.
Professor Jeon, Pyung of SMC’s Department of Radiology, who led the procedure, is a recognized authority in aneurysm stenting and has extensive experience with first-generation flow diverter stents. His expertise, especially in treating large aneurysms exceeding 10mm, was pivotal to this pioneering operation.
Professor Jeon expressed his enthusiasm about the milestone, stating, “It is an honor to have performed the world’s first procedure with this advanced stent equipment. This achievement highlights the recognition of South Korean medical expertise by a leading American company.” He further noted, “This experience underscores the global advancement of Korean medicine. We remain committed to exploring innovative treatment techniques that benefit our patients.”